The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia: Is It a Practice Effect?
Abstract
CONTEXT: Cognitive impairment in schizophrenia is frequent, involves multiple domains, and is enduring. Numerous recent clinical trials have suggested that second-generation antipsychotic medications significantly enhance cognition in schizophrenia. However, none of these studies included healthy controls undergoing repeated testing to assess the possibility that improvements might reflect simple practice effects. OBJECTIVE: To report the results on cognition of a randomized comparison of 2 widely prescribed second-generation antipsychotic medications, olanzapine and risperidone, in patients with first-episode schizophrenia and a healthy control group. DESIGN: Randomized clinical trial. SETTING: Hospital-based research units. Patients A total of 104 participants with first-episode schizophrenia and 84 healthy controls. MAIN OUTCOME MEASURES: Cognitive assessment of all study participants occurred at baseline, 6 weeks later, and 16 weeks later. Neurocognitive tests included measures of working memory and attention, speed, motor function, episodic memory, and executive function. RESULTS: No differential drug effects were observed. Of 16 cognitive measures, 9 demonstrated improvement over time and only 2 demonstrated greater rates of change than those observed in the healthy control group undergoing repeated assessment. The composite effect size for cognitive change was 0.33 in the healthy control group (attributed to practice) and 0.36 in the patients with first-episode schizophrenia. Improvements in cognition in the first-episode schizophrenia group could not be accounted for by medication dose, demographic variables, or intellectual level. CONCLUSIONS: The cognitive improvements observed in the trial were consistent in magnitude with practice effects observed in healthy controls, suggesting that some of the improvements in cognition in the first-episode schizophrenia group may have been due to practice effects (ie, exposure, familiarity, and/or procedural learning). Our results also indicated that differential medication effects on cognition were small. We believe that these findings have important implications for drug discovery and the design of registration trials that attempt to demonstrate cognitive enhancement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences
Cohen, P., Cohen, P., West, S. G., & Aiken, L. S. (2014) · Psychology Press eBooks · doi:10.4324/9781410606266 · Cited by 20,737
Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences.
Tufte, E. R., Cohen, J., & Cohen, P. (1979) · Journal of the American Statistical Association · doi:10.2307/2286442 · Cited by 5,180
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Toward an instance theory of automatization.
Logan, G. D. (1988) · Psychological Review · doi:10.1037/0033-295x.95.4.492 · Cited by 3,466
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
Saykin, A. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020048005 · Cited by 1,086
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Neuropsychology of First-Episode Schizophrenia: Initial Characterization and Clinical Correlates
Bilder, R. M., Goldman, R. S., Robinson, D., Reiter, G., Bell, L., Bates, J. A., Pappadopulos, E., Willson, D. F., Alvir, J. M. J., Woerner, M. G., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.549 · Cited by 906
Self-citationBowie, C. R., Reichenberg, A., Patterson, T. L., Heaton, R. K., & Harvey, P. D. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.418 · Cited by 763
Human Functional Neuroimaging of Brain Changes Associated with Practice
Kelly, A. M. C., & Garavan, H. (2005) · Cerebral Cortex · doi:10.1093/cercor/bhi005 · Cited by 752
Cited by
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Neurocognition in first-episode schizophrenia: a meta-analytic review.
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009) · Neuropsychology · doi:10.1037/a0014708 · Cited by 1,130
Schizophrenia Is a Cognitive Illness: Time for a Change in Focus
Kahn, R. S., & Keefe, R. S. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.155 · Cited by 825
A systematic review and meta-analysis of exercise interventions in schizophrenia patients
Firth, J., Cotter, J., Elliott, R., French, P., & Yung, A. R. (2015) · Psychological Medicine · doi:10.1017/s0033291714003110 · Cited by 600
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
Firth, J., Stubbs, B., Rosenbaum, S., Vancampfort, D., Malchow, B., Schuch, F., Elliott, R., Nuechterlein, K. H., & Yung, A. R. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw115 · Cited by 488
Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing
Bartels, C., Wegrzyn, M., Wiedl, A., Ackermann, V., & Ehrenreich, H. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-118 · Cited by 444
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426
Schizophrenia, “Just the Facts”: What we know in 2008
Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.022 · Cited by 409
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Goldberg, T. E., Harvey, P. D., Wesnes, K. A., Snyder, P. J., & Schneider, L. S. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.003 · Cited by 343
Self-citationDavidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W. W., Keefe, R. S., Boter, H., Keet, I. P. M., Prelipceanu, D., Rybakowski, J. K., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08060806 · Cited by 320
Lewis, D. A., Cho, R. Y., Carter, C. S., Eklund, K., Forster, S., Kelly, M. A., & Montrose, D. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030395 · Cited by 292
Eack, S. M., Greenwald, D. P., Hogarty, S. S., Cooley, S. J., DiBarry, A. L., Montrose, D. M., & Keshavan, M. S. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1468 · Cited by 289
Vigen, C. L. P., Mack, W. J., Keefe, R. S. E., Sano, M., Sultzer, D. L., Stroup, T. S., Dagerman, K. S., Hsiao, J. K., Lebowitz, B. D., Lyketsos, C. G., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.08121844 · Cited by 281
Nielsen, R. E., Levander, S., Kjaersdam Telléus, G., Jensen, S. O. W., Østergaard Christensen, T., & Leucht, S. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12374 · Cited by 270
The Cognitive Neuroscience of Memory Function and Dysfunction in Schizophrenia
Ranganath, C., Minzenberg, M. J., & Ragland, J. D. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.011 · Cited by 263
Keefe, R. S. E., Fox, K. H., Harvey, P. D., Cucchiaro, J., Siu, C., & Loebel, A. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.09.015 · Cited by 237
Rethinking schizophrenia in the context of normal neurodevelopment
Catts, V. S., Fung, S. J., Long, L. E., Joshi, D., Vercammen, A., Allen, K. M., Fillman, S. G., Rothmond, D. A., Sinclair, D., Tiwari, Y., et al. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00060 · Cited by 206
Gandal, M. J., Sisti, J., Klook, K., Ortinski, P. I., Leitman, V, Liang, Y., Thieu, T., Anderson, R., Pierce, R. C., Jonak, G., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.69 · Cited by 204
“, working memory deficit) with risperidone,(51) despite the drug’s lack of clinical efficacy on this domain.(80,81) Thus, although these studies have added important mechanistic insights, we employed a model with clear phenotypic deficits that would favor false-negative predictive validity as a conser-”
BackgroundKandola, A., Hendrikse, J., Lucassen, P. J., & Yücel, M. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00373 · Cited by 155
“Furthermore, no antipsychotic medication (Goldberg et al., 2007; Tybura et al., 2013) or other pharmacological intervention (Keefe et al., 2013) has been consistently demonstrated to alleviate the cognitive deficits associated with schizophrenia and in cases where the medication is anticholinergic,…”
Buchanan, R. W., Keefe, R. S. E., Umbricht, D., Green, M. F., Laughren, T., & Marder, S. R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq038 · Cited by 154
Ouhaz, Z., Fleming, H., & Mitchell, A. S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00033 · Cited by 142
“…deserve particular emphasis since they may predict poor functional outcome more strongly than either positive or negative symptoms alone (Green, 1996; Green et al., 2000; Tabarés-Seisdedos et al., 2008), and remain refractory to current treatments (Hagan and Jones, 2005; Goldberg et al., 2007).”
BackgroundRodefer, J. S., Nguyen, T. N., Karlsson, J.-J., & Arnt, J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301654 · Cited by 126
McClay, J. L., Adkins, D. E., Åberg, K., Bukszár, J., Khachane, A. N., Keefe, R. S. E., Perkins, D. O., McEvoy, J. P., Stroup, T. S., Vann, R. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.193 · Cited by 124
Cognitive deficits in recent-onset and chronic schizophrenia
Sponheim, S. R., Jung, R. E., Seidman, L. J., Mesholam-Gately, R. I., Manoach, D. S., O’Leary, D. S., Ho, B. C., Andreasen, N. C., Lauriello, J., & Schulz, S. C. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.09.010 · Cited by 123
The effects of physical exercise in schizophrenia and affective disorders.
Malchow, B., Reich-Erkelenz, D., Oertel-Knöchel, V., Keller, K., Hasan, A., Schmitt, A., Scheewe, T. W., Cahn, W., Kahn, R. S., & Falkai, P. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0423-2 · Cited by 111
Firth, J., Stubbs, B., Vancampfort, D., Firth, J. A., Large, M., Rosenbaum, S., Hallgren, M., Ward, P. B., Sarris, J., & Yung, A. R. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby034 · Cited by 105
Bruno, A., Micò, U., Pandolfo, G., Mallamace, D., Abenavoli, E., Di Nardo, F., D’Arrigo, C., Spina, E., Zoccali, R. A., & Muscatello, M. R. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431751 · Cited by 103
Fisher, M., Loewy, R., Hardy, K., Schlosser, D., & Vinogradov, S. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143134 · Cited by 71
Broader visual orientation tuning in patients with schizophrenia
Rokem, A., Yoon, J. H., Ooms, R. E., Maddock, R. J., Minzenberg, M. J., & Silver, M. A. (2011) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2011.00127 · Cited by 50
Kim, S.-W., Shin, I.-S., Kim, J.-M., Lee, J.-H., Lee, Y.-H., Yang, S.-J., & Yoon, J.-S. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31819a68b5 · Cited by 47
Cadena, E. J., White, D. M., Kraguljac, N. V., Reid, M. A., & Lahti, A. C. (2018) · npj Schizophrenia · doi:10.1038/s41537-018-0051-y · Cited by 36
Carli, M., Calcagno, E., Mainini, E., Arnt, J., & Invernizzi, R. W. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2066-6 · Cited by 20
Yin, J., Sun, Y., Zhu, Y., Alifujiang, H., Wang, Y., An, S., Huang, H., Fu, X., Deng, H., & Chen, Y. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.103959 · Cited by 15
Yoga for Schizophrenia: a Review of Efficacy and Neurobiology
Dodell-Feder, D., Gates, A., Anthony, D., & Agarkar, S. (2017) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-017-0125-6 · Cited by 7
Metadata
- Authors
- Goldberg, T. E., Goldman, R. S., Burdick, K. E., Malhotra, A. K., Lencz, T., Patel, R. C., Woerner, M. G., Schooler, N. R., Kane, J. M., & Robinson, D. G.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2007-10-01
- Volume
- 64
- Issue
- 10
- Pages
- 1115
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2073442736
- Cited by
- 394
- References
- 45
- FWCI
- 21.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.